Saturday Rounds: Week of October 10–16, 2026

Randomized evidence, fragile risk appetite. Weekly Biotech Signal Review · Completed reporting week: October 10–October 16, 2026 · Published October 17, 2026 Report at a glance: A randomized NEJM trial favored a chemotherapy-free regimen in Ph+ ALL, the FDA widened Anktiva’s label, and in vivo…